Tezepelumab Cuts COPD Exacerbation Rate in High-Risk Population: COURSE Trial Highlights with Dave Singh, MD
Dave Singh, MD, lead investigator for the phase 2a COURSE trial of tezepelumab in moderate to very severe COPD, highlights the drug's promise in vulnerable groups.
ETHOS Post-Hoc Analysis: Dave Singh, MD, Highlights Breztri Reduction of Cardiopulmonary Risk in COPD
The triple therapy cut risk of a first cardiopulmonary event by 20% vs dual therapy in addition to significantly reducing COPD exacerbations, PI Singh told Patient Care.
Key Messages and Strategies: Managing and Following Up Patients Receiving Teplizumab
Optimizing the Teplizumab Infusion Process: The Vital Role of Key Contacts and Champions
Insights from the TN-10 Study and its Impact on T1D Stage Progression
Delaying T1D Progression: Strategies and Interventions for Optimal Management
Emphasizing Early T1D Intervention: Avoiding Complications Associated with Delayed Treatment
Comprehensive Antibody Screening in T1D: Understanding Types and Relevance
Antibody Screening in T1D: Identifying High-Risk Populations and Best Screening Practices
Optimizing T1D Care: Collaborative Approaches and Expert Insights
Understanding T1D Progression: The Importance of Recognizing Different Stages
Navigating T1D: From Complications to Stage Progression
Clinical Insights: Addressing the Impact of Type 1 Diabetes (T1D) Burden
Novel Web App for OTC Statin Medication: TACTiC Study Lead Author Steven Nissen, MD, Explains Findings
Dr Nissen discusses the impetus behind the study, the potential public health implications of the results, and more.
The Pipeline for New MASLD & MASH Treatments is Promising, says Naim Alkhouri, MD
Following the landmark FDA approval of resmetirom for MASH with fibrosis, hepatologist and researcher Alkhouri describes more mid- and late-stage candidates.
A MASLD Mantra to Practice By: Screen, Stage, Treat
Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.
The FDA Approval of Resmetirom for MASH Changes Everything—for Patients and their Physicians
Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.
Early Detection of MASLD in Primary Care: The Essentials with Naim Alkhouri, MD
Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.
The Rate of Undetected MASLD in the US is a Sobering Statistic, says Expert Hepatologist Naim Alkhouri, MD
Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.
After the CLEAR Outcomes Trial, ASCVD Risk Reduction Remains a Global Challenge, PI Nissen Says
The study that led to an historic expanded label for bempedoic acid must be followed by more like it, said Steven Nissen, MD. There is much more to do.
Bempedoic Acid Should be In Everyone's CVD Prevention Toolbox, According to Steven Nissen, MD
Statin intolerance is a "vexing" problem for primary care clinicians and specialists alike. Bempedoic acid fills a distinct need in that tool box.
Steven Nissen, MD, Discusses the "Sweet Spot" for Bempedoic Acid Among Non-Statin Therapies
The CLEAR Outcomes PI explains the patient selection approach for bempedoic acid, now approved to reduce risk of CV events in addition to lowering LDL-C.
How the CLEAR Outcomes Trial Made CV Risk Reduction History, with Lead Investigator Steven Nissen, MD
Bempedoic acid became the first nonstatin LDL-C lowering medication indicated to reduce CV risk in both primary and secondary prevention. Nissen explains how.
Obesity & Chronic Pain Management: An Expert Discussion
Monu Khanna, MD, discusses challenges in managing pain in patients with obesity, effective pharmacological and nonpharmacological therapies, and more.
Obesity and Venous Disease: Expert Details Optimal Treatment Options
Shagun Bindlish, MD, board member of the American Diabetes Association, details available options for treating venous disease in patients with obesity.
Secondary CVD Prevention Requires Much More than "Usual Care," Says Michael Koren, MD,
ACC.24: Individuals with ASCVD not at target LDL-C on maximum statin therapy need immediate intervention and one that works, said V-INITIATE primary investigator.
The Inclisiran Impact on PCSK9: A Primary Care Primer
ACC.24: Michael Koren, MD, highlights how the nonstatin lipid-lowering medication's mechanism of action against PCSK9 differs from others in the category.
Michael J Koren, MD, Reviews Success of "Inclisiran First" Strategy and Implications for Clinical Practice
ACC.24: The primary investigator of the VICTORION-INITIATE study explains why new strategies are needed to accelerate LDL-C lowering in high-risk individuals.
Self-Administered Flu Vaccine May be “Powerful Tool” in Immunization Efforts, Says Expert
Ravi Jhaveri, MD, provides an overview of AstraZeneca's FluMist Quadrivalent vaccine and discusses why it could help increase vaccination rates.
Steven Nissen, MD, Discusses Historic Bempedoic Acid Labeling for CV Risk Reduction
CLEAR Outcomes PI Steven Nissen, MD, links findings from the pivotal trial with labeling updates that make bempedoic acid the only nonstatin agent approved to reduce CV risk.
